Addressing treatment challenges in atopic dermatitis with novel topical therapies

References

• Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–94.
   PubMed Web of Science ®Google Scholar
• Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131:295.
   PubMed Web of Science ®Google Scholar
• Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2010;163:12–26.
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22:125–37.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132:1132–8.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis. 2014;25:107–14.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Curr Allergy Asthma Rep. 2008;8:306–11.
   PubMed Web of Science ®Google Scholar
• Hong J, Buddenkotte J, Berger TG, Steinhoff M. Management of itch in atopic dermatitis. Semin Cutan Med Surg. 2011;30:71–86.
   PubMed Web of Science ®Google Scholar
• Blume-Peytavi U, Metz M. Atopic dermatitis in children: management of pruritus. J Eur Acad Dermatol Venereol. 2012;26:2–8.
   PubMed Web of Science ®Google Scholar
• Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab. 2015;66:34–40.
   PubMed Web of Science ®Google Scholar
• Chamlin SL, Frieden IJ, Williams ML, Chren MM. Effects of atopic dermatitis on young American children and their families. Pediatrics. 2004;114:607–11.
   PubMed Web of Science ®Google Scholar
• Chang YS, Chou YT, Lee JH, et al. Atopic dermatitis, melatonin, and sleep disturbance. Pediatrics. 2014;134:e397–405.
   PubMed Web of Science ®Google Scholar
• Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema. Cochrane Database Syst Rev. 2012;2:CD005205.
   PubMed Web of Science ®Google Scholar
• Halvorsen JA, Lien L, Dalgard F, et al. Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study. J Invest Dermatol. 2014;134:1847–54.
   PubMed Web of Science ®Google Scholar
• Suh DC, Sung J, Gause D, et al. Economic burden of atopic manifestations in patients with atopic dermatitis-analysis of administrative claims. J Manag Care Pharm. 2007;13:778–89.
   PubMed Web of Science ®Google Scholar
• Silverberg JI. Association between childhood eczema and headaches: an analysis of 19 US population-based studies. J Allergy Clin Immunol. 2016;137:492–99.
   PubMed Web of Science ®Google Scholar
• Garg N, Silverberg JI. Association between childhood allergic disease, psychological comorbidity, and injury requiring medical attention. Ann Allergy Asthma Immunol. 2014;112:525–32.
   PubMed Web of Science ®Google Scholar
• Zhang A, Silverberg JI. Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis. J Am Acad Dermatol. 2015;72:606–16.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242:233–46.
   PubMed Web of Science ®Google Scholar
• Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014:354250.
   PubMedGoogle Scholar
• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387:1109–22.
   PubMed Web of Science ®Google Scholar
• Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int. 2013;62:151–61.
   PubMed Web of Science ®Google Scholar
• Arkwright PD, Motala C, Subramanian H, et al. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract. 2013;1:142–51.
   PubMed Web of Science ®Google Scholar
• Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2015. [Epub ahead of print]. doi:10.1007/s12016-015-8488-5.
   PubMedGoogle Scholar
• Wilson SR, Gerhold KA, Bifolck-Fisher A, et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat Neurosci. 2011;14:595–602.
   PubMed Web of Science ®Google Scholar
• Rathi SK, D'Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol. 2012;57:251–9.
   PubMedGoogle Scholar
• Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs. 2013;15:303–10.
   PubMed Web of Science ®Google Scholar
• Walling HW, Swick BL. Update on the management of chronic eczema: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol. 2010;3:99–117.
   PubMedGoogle Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116–32.
   PubMed Web of Science ®Google Scholar
• Margolis JS, Abuabara K, Bilker W, et al. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol. 2014;150:593–600.
   PubMed Web of Science ®Google Scholar
• Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15.
   PubMed Web of Science ®Google Scholar
• Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal “steroid addiction” in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72:541–9.
   PubMed Web of Science ®Google Scholar
• Fukaya M, Sato K, Sato M, et al. Topical steroid addiction in atopic dermatitis. Drug Healthcare Patient Saf. 2014;6:131–8.
   PubMedGoogle Scholar
• Takahashi-Ando N, Jones MA, Fujisawa S, Hama R. Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional survey. Drug Healthcare Patient Saf. 2015;7:57–62.
   PubMedGoogle Scholar
• Protopic (tacrolimus) Ointment 0.03% [prescribing information]. Toyama City, Japan: Astellas Pharma Tech Co., Ltd., 2012.
   Google Scholar
• Elidel (pimecrolimus) Cream, 1% for Topical use [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America, 2014.
   Google Scholar
• Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14:163–78.
   PubMed Web of Science ®Google Scholar
• Manthripragada A. Addendum: update on Calcineurin Inhibitor Pediatric Literature Review. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology; 2011. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255140.pdf. Accessed December 9, 2015.
   Google Scholar
• van den Bogaard EH, Bergboer JG, Vonk-Bergers M, et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest. 2013;123:917–27.
   PubMed Web of Science ®Google Scholar
• Saeedi M, Morteza-Semnani K, Ghoreishi MR. The treatment of atopic dermatitis with licorice gel. J Dermatol Treat. 2003;14:153–7.
   PubMedGoogle Scholar
• Kobayashi H, Takahashi K, Mizuno N, et al. An alternative approach to atopic dermatitis: part I-case-series presentation. Evid Based Complement Alternat Med. 2004;1:49–62.
   PubMed Web of Science ®Google Scholar
• Pilgrim J. Methylprednisolone aceponate 0.1% ointment/cream [Advantan®]. New Zealand Research Review. 2012. Available from http://www.researchreview.co.nz/nz/Clinical-Area/General-Medicine/Dermatology/Methylprednisolone-aceponate-ADVANTAN®-reviewed-by.aspx. Accessed February 10, 2016.
   Google Scholar
• Nowicki R, Trzeciak M, Wilkowska A, et al. Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology. Postep Derm Alergol. 2015;32:239–49.
   PubMed Web of Science ®Google Scholar
• Eastman WJ, Malahias S, Delconte J, Di Benedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014;94:46–53.
   PubMed Web of Science ®Google Scholar
• Grewe SR, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol. 1982;70:452–7.
   PubMed Web of Science ®Google Scholar
• Ishii N, Shirato M, Wakita H, et al. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013;346:105–12.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996;107:51–6.
   PubMed Web of Science ®Google Scholar
• Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6:17–26.
   PubMedGoogle Scholar
• Murrell D, Gebauer K, Spelman L, Zane LT. Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study. J Drugs Dermatol. 2015;14:1108–12.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009;10:1236–42.
   PubMed Web of Science ®Google Scholar
• Zane LT, Kircik L, Call R, et al. AN2728 topical ointment, 2% in patients 2 to 17 years of age with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure (MUSE) study. Pediatr Dermatol. In press.
   PubMed Web of Science ®Google Scholar
• Tom WL, Van SM, Chanda S, Zane LT. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study. Pediatr Dermatol. 2016;33:150–9.
   PubMed Web of Science ®Google Scholar
• Stein Gold LF, Spelman L, Spellman MC, et al. A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol. 2015;14:1394–9.
   PubMed Web of Science ®Google Scholar
• Kircik L, Call R, Tschen E, et al. Maximal use systemic exposure (MUSE) study evaluating AN2728, a novel boron-based small molecule, for the treatment of pediatric and adolescent subjects with mild-to-moderate atopic dermatitis. Presented at: Orlando Dermatology Aesthetic & Clinical Conference. 15–18 January 2016; Orlando, Florida.
   Google Scholar
• Ohba F, Nomoto M, Hojo S, Akama H. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis. J Dermatol Treat. 2015;27:1–6.
   PubMed Web of Science ®Google Scholar
• Furue M, Kitahara Y, Akama H, et al. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol. 2014;41:577–85.
   PubMed Web of Science ®Google Scholar
• Felding J, Sorensen MD, Poulsen TD, et al. Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)-acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis. J Med Chem. 2014;57:5893–903.
   PubMed Web of Science ®Google Scholar